Post hoc analysis of phase III ASCLEPIOS I and II trials of ofatumumab in treatment of relapsing multiple sclerosis reported at conference

Analysis (n=1882) showed that compared to teriflunomide, a greater proportion of patients treated with ofatumumab, an anti-CD20 monoclonal antibody, achieved no evidence of disease activity in year 1 (47.0% vs 24.5%; p<0.001) and in year 2 (87.8% vs 48.2%; p<0.001).

SPS commentary:

In Feb 2020, the FDA and European Medicines Agency accepted the filing of a licensing application for ofatumumab as a self-administered once-monthly subcutaneous injection, for treatment of relapsing forms of multiple sclerosis in adults.

Biospace Inc.